Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2023 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update

Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet® Received feedback from FDA on...
May 08, 2023 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform

Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia’s proprietary development...
May 04, 2023 08:00 ET | Source: Eyenovia, Inc.

Eyenovia to Report First Quarter 2023 Results on Thursday, May 11

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
April 24, 2023 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Poster Presentation at ARVO 2023

NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
March 30, 2023 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia...
March 23, 2023 08:00 ET | Source: Eyenovia, Inc.

Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30

NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with...
February 28, 2023 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
February 15, 2023 09:51 ET | Source: Eyenovia, Inc.

Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals

NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
January 12, 2023 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
December 20, 2022 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Participation at the 2023 International Consumer Electronics Show

Booth to feature “smart” remote patient monitoring capabilities being developed for future versions of the company’s novel Optejet® drug delivery technology Company to occupy booth 8311 NEW YORK,...